ALLMedicine™ Immunodeficiencies Center

Mar 16th, 2023 - Medical Care Conjunctivitis, otitis media, sinusitis, bronchitis, and tracheobronchitis Most patients with conjunctivitis, otitis media, sinusitis, bronchitis, and tracheobronchitis due to S pneumoniae infection can be treated on an outpatient bas...

Mar 16th, 2023 - Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including administration of booster doses, continues to be the most effective method for controlling COVID-19-related complications including progression to severe i...

Mar 14th, 2023 - Chronic pulmonary aspergillosis is a major global infection in individuals with preexisting structural lung diseases and those with immunodeficiencies, in particular cytokine defects. Current treatment options are confined to just three drug class...

Mar 10th, 2023 - There are two conditioning regimens in this protocol for children >6 months. Alemtuzumab (Campath), Fludarabine and Melphalan are used. The regimens differ by the timing and dosing of Alemtuzumab (Campath). The two timings are distal and intermedi...

Mar 9th, 2023 - This protocol is designed as an adjunct to other National Institutes of Health (NIH) IRB approved protocols that allow for genetic testing, which may include those that are screening protocols for patients with rare primary immunodeficiency or imm...

Feb 23rd, 2020 - The European Position Paper on Rhinosinusitis and Nasal Polyps 2020 is the update of similar evidence based position papers published in 2005 and 2007 and 2012. The core objective of the EPOS2020 guideline is to provide revised, up-to-date and cle...

Mar 10th, 2023 - There are two conditioning regimens in this protocol for children >6 months. Alemtuzumab (Campath), Fludarabine and Melphalan are used. The regimens differ by the timing and dosing of Alemtuzumab (Campath). The two timings are distal and intermedi...

Mar 9th, 2023 - This protocol is designed as an adjunct to other National Institutes of Health (NIH) IRB approved protocols that allow for genetic testing, which may include those that are screening protocols for patients with rare primary immunodeficiency or imm...

Mar 6th, 2023 - Allogeneic transplant using human leukocyte antigen (HLA) matched donors, both related and unrelated, has proven curative for patients with various immunodeficiencies, including those with ongoing infections. However, donor availability remains a ...

Feb 27th, 2023 - Graft-versus-host-disease (GVHD) is a disease phenomenon that occurs when immune cells of the donor recognize and attack healthy tissue within the transplant recipient, or host. It is ultimately the result of the same immunological mechanisms that...

Feb 23rd, 2023 - Study Description: This prospective cohort study will assess the pre- and post vaccination immune responses in individuals with select immunodeficiencies and immune dysregulations compared to healthy volunteers who receive a coronavirus disease 20...

Sep 8th, 2022 - (Reuters) - Spanish pharmaceutical company Grifols has struck a 15-year renewable collaboration agreement with Canada's national blood authority to increase the supply of immunoglobulins (Ig) in the country, the company said on Wednesday. Under th...

Apr 28th, 2022 - This transcript has been edited for clarity. Hi. I'm Art Caplan. I'm at the Division of Medical Ethics at New York University's Grossman School of Medicine. Masks are in the news again but not necessarily for good reasons. A federal court judge in...

Feb 7th, 2022 - The study covered in this summary was published on medRxiv.org as a preprint and has not yet been peer reviewed. Key Takeaways Patients with primary immunodeficiencies, also known as inborn errors of immunity (IEIs), are at higher risk for early-o...

Sep 22nd, 2021 - The U.S. policy that calls for giving all recommended vaccines to new immigrants as soon as they step off the metaphorical boat may need a tweak, said researchers who reported a fatal outcome for one teenage girl. The 17-year-old from Central Amer...

May 11th, 2021 - A novel gene therapy for severe combined immunodeficiency from adenosine deaminase deficiency (ADA-SCID) restored immune cell counts without death or need for enzyme replacement therapy, researchers reported. Survival without needing to re-initiat...